Loading
Bispecific antibodies such as teclistamab and elranatamab for myeloma, or glofitamab and epcoritamab for lymphoma, link T cells to cancer cells. The first doses are built up in steps to lower the risk of cytokine release syndrome (fever, low blood pressure) and confusion. Some countries do this in hospital; others let chosen patients go home between doses with a trained carer and a 24-hour number.
Step-up dosing (a small priming dose, then one or more intermediate doses before the full dose) is the standard way to start T-cell engaging bispecifics; the schedule, premedication and observation period are set by each product's label, which was not read here. The European Myeloma Network (2023) recommends premedication, frequent assessment for CRS and step-up dosing, with corticosteroids and tocilizumab for CRS and anakinra for refractory cases. CRS and ICANS are graded on the ASTCT scale.
The 2026 European Delphi consensus on BCMA bispecifics in myeloma (84 statements, 75% or more agreement; Pfizer-funded) restricts outpatient step-up dosing to patients with ECOG 0 to 2, low tumour burden, stable organ function, a neutrophil count of at least 1000/mm3, no neurological symptoms or active infection, a trained adult carer available 24 hours a day, and a home within 60 minutes of a centre with haematology and intensive care. Centres must have a clinician experienced in CRS and ICANS during dosing hours, two doses of tocilizumab in a known place, dexamethasone, high-dose steroids and anakinra, written escalation protocols and access to intensive care. Neutropenia from high tumour burden should not be corrected with G-CSF before step-up dosing. Antiviral and Pneumocystis prophylaxis are mandatory for all, with baseline CMV testing and immunoglobulin replacement when IgG is under 400 mg/dL or infections recur. Transfer to a community centre only after the full step-up phase, afebrile for 24 hours and with no toxicity, with a written handover.
A 2026 viewpoint notes that current US labels recommend inpatient administration during step-up dosing. The CD3xCD20 consensus (2024) covers the lymphoma bispecifics separately and was read only as an abstract.
Why: Building up the dose lets the immune system adjust and lowers the risk and severity of CRS.
“Recommended measures include premedication, frequent assessing for symptoms and severity of cytokine release syndrome, step-up dosing for several BsAbs and some CAR T-cell therapies; corticosteroids; and tocilizumab in the case of cytokine release syndrome.”
Why: Each bispecific has its own licensed schedule; outpatient observation must match it.
“Following each step‐up dose, patients must be observed for vital signs and neurological function for a minimum defined period as specified in the SmPC.”
Why: Infections are the main cause of serious harm on these drugs; prophylaxis lowers the risk.
“Antiviral (e.g., acyclovir) and PJP prophylaxis (e.g., co‐trimoxazole) are mandatory for all patients.”
Why: BCMA bispecifics deplete antibody-making cells, leaving people unable to fight bacteria.
“Patients with trough IgG < 400 mg/dL should receive IV or SC Ig every 4 weeks and be retested every month until IgG recovers (including after completion of treatment).”
Why: Growth factors may raise the risk of CRS, and neutropenia from heavy marrow involvement itself signals higher CRS risk.
“Neutropenia (defined as an absolute neutrophil count < 1000/mm 3 ) should not be resolved with G‐CSF prior to SUD due to the risk of CRS.”
Why: High tumour burden and frailty raise the risk of severe CRS, which is safer to manage on a ward.
“Outpatient SUD should only be considered for patients with low tumor burden (where high tumor burden is defined as BMPCs ≥ 60%, presence of ≥ 1 focal lesion ≥ 5 mm [bone or soft tissue] on MRI or PET–CT, M‐spike ≥ 30 g/L, LDH > ULN) and stable disease status.”
Why: Someone must notice fever or confusion and get the patient back quickly.
“Patients must reside within 60 min (by ambulance, car, etc.) of a treatment center that provides both hematology or internal medicine expertise and ICU‐level care.”
Why: CRS and ICANS can begin within hours and must be treated without delay.
“Outpatient SUD centers must have tocilizumab (two doses) available in a known and accessible location.”
Why: Clear triggers mean every nurse escalates at the same point.
“SOPs must define observation duration and escalation thresholds for CRS and ICANS, using established grading systems such as ASTCT and ICE.”
Why: The same scale is used for CAR T cells and bispecifics, so treatment algorithms can be shared.
“CRS grade is determined by the more severe event: hypotension or hypoxia not attributable to any other cause.”
Why: Fever, confusion and breathlessness at home need an immediate call.
“Education on CRS/ICANS must include both verbal explanations and written materials tailored to BCMA‐BsAb toxicities.”
Why: Most CRS happens during step-up; moving care earlier risks it starting away from the team that knows the drug.
“Patients must be afebrile (≥ 24 h) and hemodynamically stable before being considered for transition to community care.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Step-up dosing with premedication and close CRS monitoring is common ground (European Myeloma Network 2023; IMWG 2024). Where step-up doses are given is not: a 2026 viewpoint notes that current US labels recommend inpatient administration during step-up dosing, while the 2026 European Delphi consensus sets criteria for doing it as an outpatient in selected patients (low tumour burden, ECOG 0 to 2, trained carer, within 60 minutes of intensive care, tocilizumab on site). That consensus is the most detailed source read and it was funded by Pfizer, a manufacturer of a BCMA bispecific. Infection prophylaxis (antiviral and Pneumocystis for all, immunoglobulin when IgG is under 400 mg/dL) is shared across the myeloma sources. The product labels, which set the schedules, were not read.
European Myeloma Network, The Lancet Oncology 2023 · International Myeloma Working Group, The Lancet Oncology 2024 · eJHaem (European Delphi panel; funded by Pfizer) 2026 · JMIR (viewpoint) 2026
Where it differs: Current US labelling recommends inpatient administration during step-up dosing, which concentrates treatment in academic centres.
Evidence: Regulatory labelling, as described in a 2026 viewpoint; the labels themselves were not read.
Where it differs: Uses remote patient monitoring to support outpatient step-up dosing in academic and community practices.
Evidence: Authors' real-world experience and case examples; not a trial.
Where it differs: An international panel of physicians, advanced practitioners, nurses and pharmacists set recommendations specific to CD3xCD20 bispecifics, noting that the timing, nature and severity of their toxicities differ from CAR T cells.
Evidence: Consensus recommendations; abstract read only.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Antiviral and Pneumocystis prophylaxis for all patients on BCMA bispecifics | consensus, 100% agreement | eJHaem (European Delphi panel; funded by Pfizer) 2026 |
| Outpatient step-up dosing only for low tumour burden and stable disease | consensus, 84% agreement | eJHaem (European Delphi panel; funded by Pfizer) 2026 |
| Live within 60 minutes of a centre with haematology and intensive care | consensus, 100% agreement | eJHaem (European Delphi panel; funded by Pfizer) 2026 |
| Two doses of tocilizumab on site for outpatient step-up dosing | consensus, 97% agreement | eJHaem (European Delphi panel; funded by Pfizer) 2026 |
| No G-CSF to correct neutropenia before step-up dosing | consensus, 79% agreement | eJHaem (European Delphi panel; funded by Pfizer) 2026 |
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Cytokine release syndrome (CRS), Dexamethasone and the tags protocol, cell-therapy.
Shares ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management, CD20 bispecific antibodies: step-up dosing, fixed duration and what it is like to take one, Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids, Immunoglobulin replacement after CAR-T, bispecifics and long anti-CD20 treatment.
Shares Cytokine release syndrome after CAR T-cell therapy: ASTCT grading, tocilizumab and steroids and the tags protocol, cell-therapy.
Shares Talquetamab, Dexamethasone, Multiple myeloma and the tags protocol, cell-therapy.
Shares Multiple myeloma and the tags protocol, cell-therapy.
Shares the tags protocol, cell-therapy.
Shares Elranatamab, Teclistamab, Epcoritamab, Glofitamab.
Shares the tags protocol, cell-therapy.